Maze Therapeutics reports success in Phase 2 kidney disease trial as cash runway extends into 2028

Maze Therapeutics (NASDAQ:MAZE), a clinical-stage biopharmaceutical company applying genetic insights to the development of precision medicines, reported its fourth-quarter and full-year 2025 financial results on Wednesday, March 25, 2026.

The company’s update was headlined by successful Phase 2 data for its lead program and a significantly bolstered balance sheet that provides a multi-year operational window.

The primary clinical highlight was the topline data from the Phase 2 HORIZON trial evaluating MZE829, an oral APOL1 inhibitor, in patients with APOL1-mediated kidney disease (AMKD).

The trial met its objectives, showing a mean reduction in urinary albumin-to-creatinine ratio (uACR) of 35.6% at week 12 across the broad AMKD population.

Notably, in a subgroup of patients with severe focal segmental glomerulosclerosis (FSGS), the mean reduction reached 61.8%.

Based on these results, Maze intends to advance MZE829 into a pivotal clinical program.

Beyond its lead candidate, Maze is expanding its mid-stage pipeline.

The company expects to initiate two Phase 2 trials for MZE782, targeting phenylketonuria (PKU) and chronic kidney disease (CKD), during 2026.

This clinical progress is supported by a stable financial foundation; Maze reported cash, cash equivalents, and marketable securities of $360 million as of year-end, providing a runway into 2028.

The company also recently secured a $20 million milestone payment related to MZE001, its Pompe disease program.

On the corporate front, Maze announced the addition of Neil Kumar, Ph.D., to its Board of Directors, bringing further industry expertise as the company prepares for late-stage development.